Biotechnology Today
more-
Philips testing finds minimal risk of patient harm in some recalled CPAP and BiPAP machines
Nearly two years after Philips first publicly raised concerns about the potential breakdown of the…
Jazz hands Zymeworks a much-needed win for biliary tract cancer drug after peek at data
Magenta halts high-dose group in leukemia trial after serious adverse events
By dropping remaining ‘off-the-shelf’ CAR-T, Celyad closes clinical pipeline to complete R&D pivot
ContraFect tries to find path forward for MRSA drug despite ‘uninterpretable’ phase 3 results
Markets
more-
Weekly Market Review – February 4, 2023
Stock Markets In the week just ended, the new year’s stock rally continued, driven in…
Bio Space
more
Vistagen buys out Pherin more than 4 years after licensing now-lead social anxiety spray
Vistagen is doubling back to a familiar face, acquiring Pherin…
Merck puts eye-popping $9.3B on the line in lopsided ADC deal with Kelun-Biotech
In one of the most lopsided biobucks deals this publication…
Merck & Co. bails on NGM eye disease collab in wake of phase 2 fail
Over a year after Merck & Co. narrowed the scope…
Global News
more
SpaceX Starlink wins permit to send internet to customers like you
SpaceX has been busy building its Starlink satellite constellation. To…
Facebook video calls soar 1000% during Italy’s lockdown
Facebook has seen usage across its platforms surge in countries…
WeWork board’s special committee is demanding that SoftBank follow through with investment
Five months after SoftBank agreed to a massive bailout of…
Weekly Market Review – February 4, 2023
Philips testing finds minimal risk of patient harm in some recalled CPAP and BiPAP machines
Jazz hands Zymeworks a much-needed win for biliary tract cancer drug after peek at data
Magenta halts high-dose group in leukemia trial after serious adverse events
By dropping remaining ‘off-the-shelf’ CAR-T, Celyad closes clinical pipeline to complete R&D pivot
Vistagen buys out Pherin more than 4 years after licensing now-lead social anxiety spray
Merck puts eye-popping $9.3B on the line in lopsided ADC deal with Kelun-Biotech
Merck & Co. bails on NGM eye disease collab in wake of phase 2 fail
Quris reels in $9M in seed funding to support AI innovations in trials
ContraFect tries to find path forward for MRSA drug despite ‘uninterpretable’ phase 3 results